**Supplementary Table 4.** Cost-effectiveness results from different hepatitis C virus screening strategies (detailed)

| Strategy | Cost ($) | | | | DALY | DALY averted | QALY in the study population | QALY in the HCV-RNA population | QALY gained | Healthcare system perspectives | | Societal perspectives | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Screening | Treatment | Non-medical | Indirect | | | | | | ICER (cost/ DALY averted) | ICER (cost/ QALY gained) | ICER (cost/ DALY averted) | ICER (cost/ QALY gained) |
| Lifetime | | | | | | | | | | | | | |
| Universal screening | 2,782,402,458 | 1,067,963,921 | 356,059,152 | 19,730 | 139,097 | 267,942 | 734,602,679 | 1,117,366 | 290,803 | 8,078 | 7,443 | 5,940 | 5,473 |
| Birth cohort screening | 1,826,460,756 | 1,283,504,408 | 659,152,330 | 30,514 | 251,207 | 155,833 | 734,542,145 | 1,065,705 | 230,269 | 9,137 | 6,184 | 7,408 | 5,013 |
| High-risk group screening | 23,019,308 | 1,567,533,248 | 712,012,543 | 54,312 | 323,111 | 83,929 | 734,369,734 | 964,207 | 57,858 | Cost-saving | Cost-saving | Cost-saving | Cost-saving |
| No screening | 0 | 1,686,052,749 | 928,657,313 | 63,951 | 407,039 | Ref. | 734,311,876 | 918,878 | Ref. | Ref. | Ref. | Ref. | Ref. |
| 30 years | | | | | | | | | | | | | |
| Universal screening | 2,782,402,458 | 1,026,679,451 | 345,577,687 | 18,423 | 133,210 | 259,713 | 643,592,053 | 1,039,255 | 176,558 | 8,533 | 12,551 | 6,368 | 9,367 |
| Birth cohort screening | 1,826,460,756 | 1,225,354,027 | 638,260,102 | 28,462 | 240,729 | 152,194 | 643,558,157 | 1,005,650 | 142,662 | 9,585 | 10,225 | 7,814 | 8,336 |
| High-risk group screening | 23,019,308 | 1,488,560,763 | 697,328,493 | 51,358 | 312,066 | 80,857 | 643,449,028 | 908,430 | 33,533 | Cost-saving | Cost-saving | Cost-saving | Cost-saving |
| No screening | 0 | 1,593,052,984 | 907,774,964 | 60,382 | 392,923 | Ref. | 643,415,495 | 875,977 | Ref. | Ref. | Ref. | Ref. | Ref. |
| 15 years | | | | | | | | | | | | | |
| Universal screening | 2,782,402,458 | 877,376,798 | 278,592,853 | 13,107 | 102,252 | 169,722 | 448,247,964 | 768,560 | 84,709 | 15,414 | 30,883 | 13,100 | 26,246 |
| Birth cohort screening | 1,826,460,756 | 983,208,497 | 452,133,948 | 18,731 | 170,613 | 101,361 | 448,234,022 | 754,623 | 70,766 | 17,423 | 24,955 | 15,260 | 21,857 |
| High-risk group screening | 23,019,308 | 1,024,146,228 | 538,210,602 | 31,765 | 219,614 | 52,360 | 448,178,070 | 697,857 | 14,814 | 66 | 234 | Cost-saving | Cost-saving |
| No screening | 0 | 1,043,696,461 | 671,368,346 | 36,824 | 271,974 | Ref. | 448,163,256 | 682,988 | Ref. | Ref. | Ref. | Ref. | Ref. |

DALY, disability-adjusted life-year; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; Ref., reference.

https://doi.org/10.3350/cmh.2024.0484